LTIP555A - Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions - Google Patents

Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions

Info

Publication number
LTIP555A
LTIP555A LTIP555A LTIP555A LTIP555A LT IP555 A LTIP555 A LT IP555A LT IP555 A LTIP555 A LT IP555A LT IP555 A LTIP555 A LT IP555A LT IP555 A LTIP555 A LT IP555A
Authority
LT
Lithuania
Prior art keywords
weight
pct
parts
drugs
adminsterable
Prior art date
Application number
LTIP555A
Inventor
Udo Prof Dr Wenzel
Guenther Dipl Ing Weber
Juergen Dr Metzner
Alfred Dr Daerr
Sabine Dr Freitag
Frank-Ulrich Dr Floether
Frank-Michael Albert
Margit Dr Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of LTIP555A publication Critical patent/LTIP555A/en
Publication of LT3659B publication Critical patent/LT3659B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PCT No. PCT/DE92/00043 Sec. 371 Date Nov. 24, 1993 Sec. 102(e) Date Nov. 24, 1993 PCT Filed Jan. 23, 1992 PCT Pub. No. WO92/12710 PCT Pub. Date Aug. 6, 1992.A drug formulation administrable by mouth for the treatment of central dopamine deficiency condition, said formulation comprising 100 to 250 parts by weight of levodopa, 10 to 25 parts by weight of carbidopa, a polymer mixture in an amount of 10 to 200% based on said drugs, said polymer mixture consisting of: 0 to 100 parts by weight of a completely saponified polyvinyl alcohol having 0 to 3% residual acetyl content, a mean molecular weight of 60,000 to 80,000 and a total surface area of 0.1 m2/g to 0.18 m2/g, and 0 to 100 parts weight of a partially saponified polyvinyl alcohol having 10 to 18% residual acetyl content, a mean molecular weight of 80,000, a total surface area of 0.5 m2/g to 0.69 m2/g, and a specific pore volume of 0.2 cm3/g to 0.36 cm3/g, and an effective amount of customary galenic adjuvants.
LTIP555A 1991-01-23 1993-05-14 Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions LT3659B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (en) 1991-01-23 1991-01-23 Orally administrable drug form for the treatment of central dopamine deficiency states

Publications (2)

Publication Number Publication Date
LTIP555A true LTIP555A (en) 1994-11-25
LT3659B LT3659B (en) 1996-01-25

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP555A LT3659B (en) 1991-01-23 1993-05-14 Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions

Country Status (22)

Country Link
US (1) US5532274A (en)
EP (1) EP0568577B1 (en)
JP (1) JP3382940B2 (en)
AT (1) ATE147264T1 (en)
AU (1) AU658171B2 (en)
BG (1) BG61677B1 (en)
CA (1) CA2101164C (en)
CZ (1) CZ280847B6 (en)
DE (2) DE4101873C2 (en)
DK (1) DK0568577T3 (en)
EE (1) EE03016B1 (en)
ES (1) ES2098496T3 (en)
FI (1) FI101040B (en)
GR (1) GR3022993T3 (en)
LT (1) LT3659B (en)
LV (1) LV11103B (en)
NO (1) NO304638B1 (en)
RO (1) RO114737B1 (en)
RU (1) RU2114619C1 (en)
SK (1) SK369292A3 (en)
UA (1) UA27848C2 (en)
WO (1) WO1992012710A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (en) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
RU2173150C1 (en) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Pharmaceutical composition for biocorrection of sympathic-adrenal system
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
WO2003026626A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (en) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR USE OF LEVODOPA AND CARBIDOPA.
CA2536175C (en) * 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
JP4781352B2 (en) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド Levodopaprodrug and compositions thereof and uses thereof
WO2006103417A1 (en) * 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of parkinson's disease
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
AR055106A1 (en) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent SOLID PHARMACEUTICAL COMPOSITION OF EXTENDED LIBERATION CONTAINING CARBIDOPA AND LEVODOPA
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR101451564B1 (en) 2007-12-28 2014-11-04 임팩스 라보라토리즈, 인코포레이티드 Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (en) * 2011-07-15 2013-01-23 한미약품 주식회사 Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6506271B2 (en) 2013-10-07 2019-04-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． Mucoadhesive controlled release formulations of levodopa and / or esters of levodopa and uses thereof
JP7066351B2 (en) * 2017-08-18 2022-05-13 大原薬品工業株式会社 Levodopa-containing miniaturized tablets with good sustained release
JP6694564B1 (en) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 Binder
WO2020100933A1 (en) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 Bonding agent
US20210324222A1 (en) * 2018-11-13 2021-10-21 Japan Vam & Poval Co., Ltd. Binder
JP6695013B1 (en) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 Binder
CN115397469A (en) * 2020-04-10 2022-11-25 日本瓦姆&珀巴尔株式会社 Adhesive agent
WO2022107856A1 (en) * 2020-11-19 2022-05-27 旭化成株式会社 Porous membrane
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (en) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Carrier for drugs
DE748317C (en) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Process for the production of threads, films, tapes, hoses u. Like. From incompletely saponified polyvinyl alcohols
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (en) * 1968-10-01 1976-05-17 Merck & Co Inc PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS AND THE MOLDED PRODUCTS OBTAINED BY THEIR USE.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (en) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablet consisting of porous, fibrous carrier - and as water swellable binder polyvinyl alcohol, cellulose ether or alginate
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (en) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmaceutical preparation.
JPS5852219A (en) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd Remedy for parkinson's disease (perkinsonism)
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (en) * 1986-08-26 1989-12-11 Lejus Medical Ab A MULTIPLE-UNIT DOS COMPOSITION OF L-DOPA
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
DE3875716D1 (en) * 1987-12-31 1992-12-10 Asta Medica Ag SYNERGISTIC COMBINATION OF DECARBOXYLASE INHIBITORS AND L-DOPA PELLETS.
DE3841955A1 (en) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistic combination of decarboxylase inhibitors and L-dopa pellets

Also Published As

Publication number Publication date
LV11103B (en) 1996-06-20
DK0568577T3 (en) 1997-06-30
UA27848C2 (en) 2000-10-16
JP3382940B2 (en) 2003-03-04
ES2098496T3 (en) 1997-05-01
CZ280847B6 (en) 1996-04-17
NO304638B1 (en) 1999-01-25
DE4101873A1 (en) 1992-07-30
US5532274A (en) 1996-07-02
LT3659B (en) 1996-01-25
DE4101873C2 (en) 1993-12-09
SK278736B6 (en) 1998-02-04
FI933304L (en) 1993-07-22
NO932522L (en) 1993-07-09
GR3022993T3 (en) 1997-07-30
RO114737B1 (en) 1999-07-30
SK369292A3 (en) 1998-02-04
WO1992012710A1 (en) 1992-08-06
DE59207852D1 (en) 1997-02-20
CA2101164A1 (en) 1992-07-24
EP0568577B1 (en) 1997-01-08
JPH06504543A (en) 1994-05-26
RU2114619C1 (en) 1998-07-10
CA2101164C (en) 2001-04-24
AU1186892A (en) 1992-08-27
ATE147264T1 (en) 1997-01-15
BG97894A (en) 1994-04-29
BG61677B1 (en) 1998-03-31
EP0568577A1 (en) 1993-11-10
LV11103A (en) 1996-04-20
EE03016B1 (en) 1997-08-15
CZ369292A3 (en) 1993-09-15
FI933304A0 (en) 1993-07-22
NO932522D0 (en) 1993-07-09
FI101040B (en) 1998-04-15
AU658171B2 (en) 1995-04-06

Similar Documents

Publication Publication Date Title
LTIP555A (en) Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions
IL117356A0 (en) Controlled release pharmaceutical composition for oral administration
AP9600868A0 (en) Polymer coated tablet comprising amoxycillin and clavulanate.
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
KR880000098A (en) Chondroitin Sulfate Immunostimulatory Composition
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
IL106640A (en) Pharmaceutical compositions for the treatment and prevention of irritable bowel syndrome
ZA9426B (en) Use of riluzole for the treatment of Parkinson's Disease and Parkinsonian Syndromes
RU93051537A (en) ORAL DOSAGE FORM
DE60116662D1 (en) INHIBITION OF SYSTEMIC INFECTIONS IN PEOPLE AND SWIVELING WITH BALLASTS
US5082665A (en) Anti-snoring formulations using yohimbine
FI955837A0 (en) A process for preparing an oral solid dosage form containing diclofenac
CA2219678A1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases
KR890007728A (en) Painkiller
CA2031746A1 (en) Formulated Medicines for Enhancing the Efficacy of Beta-Lactam Antibiotics in Prophylaxis and Treatment Against Infectious Disease Due to Pathogenic Bacteria
PL312741A1 (en) Application of benidamine in treatment of pathologies caused by tnf
RU94042565A (en) Immunostimulating agent
KR930700100A (en) Veterinary Treatment
MX9705185A (en) Resin particle, medical material and pharmaceutical preparation containing said resin particle.
Homse et al. Effect of zeranol applied to suckling lambs on weight gain and oestrus onset.
SU1827797A3 (en) Medicinal preparation for eye anesthesia
CA2152280A1 (en) Use of riluzole as a radiorestorer
MX9605055A (en) Polymer coated tablet comprising amoxycillin and clavulanate.
MD1664F1 (en) Method of ulcer recidivation prophylaxis
KR890002058A (en) 2,4,6-tris-3-tert-butylamino-1, -3, -5-triazine for the prevention and treatment of epilepsy and anxiety

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20040514